

. 1928-1991: R. 1928-1991 THOMAS V SMURZYNSK RALPHIA LOREN GIULIO A DECONTI UR ANN LAMPORT HAMM THE EUZARETHA HANLEY AMY BAKER MANURAGOURAS ANTHONY A LAURENTAND KEVIN. LANNING JANEE REMILIARD DeANN FURAN SMITH PETERIC LAURO JEANNE M. DIGICIRGIO DEBRAU MILASING CIPPLE DAVIDU RIKKERS DAVID R BURNS JOHN'S CURRAN SEAN D. DETWEILER

CYNTHIA E KANIK MEGANE WILLIAMS Ph.D. RICHA NAND MICHAEL PHILLIPPS \* LISA MI DIRECCE HATHAMAY P PUSSELL " MARIA LACCOTRIPE ZACHARAK PETER A DIMATTIA MERIODAN ARMOUNT

# SENIOR COUNSEL

OF COUNSEL JEREMIAH LYNCH WILLIAM A SCOPIELD JR SIBLEY P. REPPERT

PATENT AGENTS THEODORER WEST SHAYNEY HUFF PHO DANIEL BIRC

TECHNICAL SPECIALISTS CYNTHIA M. SCROOS PETER A DINEPOL EURODNILLE JENNEERK RUSENFELD ALLAN TAME SHILL PRID CATHERINE E MOPHERSON ERICE MAGNER PhiD SHAH DIHASAN PRID JACOB G. WEINTRAUB JONATHAN M SPARKS Ph D

CRISTINE HOWLEY Phili 1. Admitted in NY only 11. Admitted in TX only

February 22, 2002

Commissioner for Patents Washington, D.C. 20231

U.S. Patent Application No.: 09/879,312

TECHCENTER GOODSOO Title: Human c-Maf Compositions and Methods of Use Therefor

Inventors: Laurie H. Glimcher and John Douhan III

Filed: June 12, 2001

Attorney's Docket No.: HUI-027CPDV1

Dear Sir:

I enclose herewith for filing in the above-identified patent application the following:

- 1. Information Disclosure Statement (2 pages):
- 2. Form PTO-449 (1 page); and
- 3. Pre-Paid Acknowledgment Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

#### Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on:

February 22, 2002

Date

111 Cynthia L. Kanik, Ph.D., Reg. No. 37,320 Respectfully submitted,

LAHIVE & COCKFIELD, LLP

Cynthia L. Kanik, Ph.D

Reg. No. 37,320

Attorney for Applicants



#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Laurie H. Glimcher and

John Douhan III

Serial No.: 09/879,312

Filed: June 12, 2001

For: Human c-Maf Compositions and Methods of Use

Therefor

Attorney Docket No.: HUI-027CPDV1

Commissioner for Patents Washington, D.C. 20231

Group Art Unit: 1632

Examiner:

TECHCENTER 160012900

### Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

February 22, 2002

Date of Signature and of Mail Deposit

Cynthia L. Kanik, Ph.D.

Registration No. 37,320 Attorney for Applicants

## INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney are aware of the following patents, publications or other information, which are cited on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these forms for the Examiner's consideration.

The present application is a Divisional Application of U.S. Serial No. 09/086,010, filed May 27, 1998 (Atty. Docket No. HUI-027CP), which is a Continuation-in-Part Application of U.S. Serial No. 09/030,579, filed February 24,

1998 (Atty. Docket No. HUI-027). All references listed on the enclosed PTO Form 1449 have been previously cited by or submitted to the Office in the prior application, and, in accordance

U.S. Serial No. 09/879.312 -2- Group Art Unit: 1632

with 37 CFR §1.98(d), copies of these references are not enclosed herewith, but will be provided upon request.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted.

LAHIVE & COCKFIELD, LLP

Cynthia L. Kanik, Ph.D. Registration No. 37,320 Attorney for Applicants

28 State Street Boston, MA 02109 (617) 227-7400

Date: February 22, 2002

GAD/CLK/RKN/alf

							Sheet 1 of 1	
REV 7 80	PATENT AND TRADEMARK OFFICE			HUI-027CPDV1		09/879,312		
	PUBLICATIONS (Use several she	CITED BY ets if neces	/ APPLICANT ssary)	Laurie H. Glimo	her and	John Douha	n III	
Day 1						1632		
3			U.S. PATENT [					
	DUCUMENT NUMBER	DATE		NAME	ULASS	SUBCLASS	FILING DATE	
		<u></u>						
		F	OREIGN PATEN	T DOCUMENTS		<del>, , , , , , , , , , , , , , , , , , , </del>		
	DUCUMENT NUMBER	DATE		C vv.		SUBCLASS	TRANSLATION YES NO	
A1	WO 97/39721	10/97	PCT		I			
	OTH	IERS (inclu	iding Author, Title	e, Date, Pertinent Pa	ges, Etc.)			
A2		Andrews, N.C. et al. "The ubiquitous subunit of erythroid transcription factor NF-E2 is a small basic-leucine zipper protein related to the v-maf oncogene," PNAS., USA, 90 (1993)						
A3	Blank et al. '	Blank et al. "Human MafG is a functional partner for p45 NF-E2 in activating globin gene expression," <i>Blood</i> 89(11):3925-35						
A4	Chesi, Marta	Chesi, Marta et al. (1998) "Frequent Dysregulation Of The c-maf Proto-Oncogene at 16q23 By						
Ā5	Ebert et al. "	Translocation to An Ig Locus In Multiple Myeloma" <i>Blood</i> . 91(12):4457-4463  Ebert et al. "A Moloney MLV-rat somatotropin fusion gene produces biologically active						
A6	Fujiwara, K.	somatotropin in a transgenic pig," <i>Mol. Endocrinol.</i> 2(3):277-83 (1988)  Fujiwara, K.T. et al. "Two new members of the <i>maf</i> oncogene family, <i>mafK</i> and <i>maff</i> , encode						
<b>A</b> 7		nuclear b-Zip proteins lacking putative trans-activator domain," <i>Oncogene</i> , 8:2371-2380 (1993)  Hammer et al. "Genetic engineering of mammalian embryos," <i>J. Animal Sci.</i> 63(1):269-78 (1986)						
A8	Ho, I-Cheng	Ho, I-Cheng et al. (1996) "The Proto-Oncogene c-maf IS Responsible For Tissue-Specific Expression Of Interleukin-4", <i>Cell</i> , 85(7):973-983						
A9	Igarashi, K.	Igarashi, K. et al. "Activity and Expression of Murine Small Maf Family Protein MafK," <i>The Journal of Biological Chemistry</i> , 270(13):7615-7624 (March 31, 1995)						
A10	Kataoka, K.	Kataoka, K. et al. "Small Maf Proteins Heterodimerize with Fos and May Act as Competitive Repressors of the NF-E2 Transcription Factor," <i>Mol. Cell. Biol.</i> , 15:2180-90 (1995)						
A11	Kataoka, K.	Kataoka, K. et al. "Structure-Function Analysis of the <i>maf</i> Oncogene Product, a Member of the b-zip Protein Family," <i>Journal of Virology</i> , 67(4):2133-2141 (April 1993)						
A12	Kataoka, K	Kataoka, K et al. GenBank™ Accession Number D28596 for Chicken gene for c-maf proto- oncogene product c-Maf, short form complete cds and long form 1 <sup>st</sup> exon.						
Ā13	Kurchner, C	. et al. Ger	Bank™ Accessio	on Number S74567 f			(proto-	
A14	Kurschner, (	C. et al. "Th		ogene Stimulates Tr				
A15				Specific Gene Expre				
A16	Swaroop, A.	Mullins et al. "Transgenesis in the rat and larger mammals," <i>J. Clin. Invest.</i> 97(7):1557-60 (1996)  Swaroop, A. et al. "A conserved retina-specific gene encodes a basic motif/leucine zipper domain", <i>Proc. Natl. Acad. Sci. USA</i> , 89:266-270 (January 1992)						
A17	Toki et al. "F	łuman sma		orm heterodimers wit	h CNC far	mily transcrip	tion factors and	

Wall et al. "Transgenic dairy cattle: genetic engineering on a large scale," J. Dairy Sci. 80(9):2213-

Date Considered

24 (1996)

Examiner

\*EXAMINER

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communic were policial.

MAR 1 2 200